Mani Foroohar Analyst Performance

Analyst at Leerink Partners

Mani Foroohar is a stock analyst at Leerink Partners across a range of sectors, covering 14 publicly traded companies. Over the past year, Mani Foroohar has issued 6 stock ratings, including buy, hold, and sell recommendations. While full access to Mani Foroohar's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Mani Foroohar's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Ranking: Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat
Average Return: 00.00% 12-Month ROI
Success Rate: 00.00% Profitable Ratings
Total Ratings: 19 Last 5 Years
Buy Recommendations: 15.79% 3 Buy Ratings
Companies Covered: 14 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	0.0%	0 ratings
Buy	15.8%	3 ratings
Hold	57.9%	11 ratings
Sell	26.3%	5 ratings

Out of 19 total stock ratings issued by Mani Foroohar at Leerink Partners, the majority (57.9%) have been Hold recommendations, followed by 26.3% Sell and 15.8% Buy.

Best & Worst Calls

Best Call
000.0%
SRPT
Jan 2020
Subscribe to MarketBeat All Access to get analyst recommendation ROI.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	85.7% of companies on NASDAQ	12 companies
NYSE	14.3% of companies on NYSE	2 companies

Mani Foroohar, an analyst at Leerink Partners, currently covers 14 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 8 companies	57.1%
	Retail/Wholesale 3 companies	21.4%
	Computer and Technology 2 companies	14.3%
	Business Services 1 company	7.1%

Mani Foroohar of Leerink Partners specializes in stock coverage within the Medical sector, with additional focus on Retail/Wholesale and Computer and Technology companies.

Coverage Industries

Industry	Percentage
MED - BIOMED/GENE 4 companies	28.6%
MED - DRUGS 3 companies	21.4%
BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC 1 company	7.1%
FINANCIAL TRANSACTION SERVICES 1 company	7.1%
COMPUTER PROGRAMMING, DATA PROCESSING, & OTHER COMPUTER RELATED 1 company	7.1%
SEMI - GENERAL 1 company	7.1%
RETAIL - RESTRNTS 1 company	7.1%
INTERNET COMMERCE 1 company	7.1%
APPAREL & ACCESSORY STORES 1 company	7.1%

Timeframe

Start Date

End Date

Rating

12-Month ROIAll ROI

Export to Excel

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating
RCKT Rocket Pharmaceuticals	10/3/2025	Lower Price Target	$3.20	$7.00	Market Perform
MRNA Moderna	8/22/2025	Lower Price Target	$27.61	$15.00	Underperform
RCKT Rocket Pharmaceuticals	5/28/2025	Reiterated Rating	$2.33	$8.00	Market Perform
LXEO Lexeo Therapeutics	3/24/2025	Lower Price Target	$3.44	$18.00	Outperform
RXRX Recursion Pharmaceuticals	2/28/2025	Lower Price Target	$7.51	$6.00	Market Perform
FDMT 4D Molecular Therapeutics	1/13/2025	Lower Price Target	$4.80	$27.00	Outperform

Stock Forecasts and Research Tools

Today's Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.